Michael W. Bonney, Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 22,500 shares at $273.75 ($6.2M) on 2025-05-15, disclosed to the SEC on 2025-05-19.
Scheduled sale ($6.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $267.14 | 549 | $147K | 2.3% |
| 2 | $267.14 | 549 | $147K | 2.3% |
| 3 | $268.56 | 729 | $196K | 3.1% |
| 4 | $268.56 | 729 | $196K | 3.1% |
| 5 | $269.79 | 245 | $66K | 1.1% |
| 6 | $269.79 | 245 |
| $66K |
| 1.1% |
| 7 | $271.68 | 431 | $117K | 1.9% |
| 8 | $271.68 | 431 | $117K | 1.9% |
| 9 | $273.16 | 660 | $180K | 2.9% |
| 10 | $273.16 | 660 | $180K | 2.9% |
| 11 | $273.75 | 882 | $241K | 3.9% |
| 12 | $273.75 | 882 | $241K | 3.9% |
| 13 | $275.63 | 301 | $83K | 1.3% |
| 14 | $275.63 | 301 | $83K | 1.3% |
| 15 | $277.16 | 1,263 | $350K | 5.6% |
| 16 | $277.16 | 1,263 | $350K | 5.6% |
| 17 | $278.01 | 1,239 | $344K | 5.5% |
| 18 | $278.01 | 1,239 | $344K | 5.5% |
| 19 | $280.03 | 432 | $121K | 1.9% |
| 20 | $280.03 | 432 | $121K | 1.9% |
| 21 | $281.10 | 372 | $105K | 1.7% |
| 22 | $281.10 | 372 | $105K | 1.7% |
| 23 | $282.03 | 802 | $226K | 3.6% |
| 24 | $282.03 | 802 | $226K | 3.6% |
| 25 | $282.81 | 1,728 | $489K | 7.8% |
| 26 | $282.81 | 1,728 | $489K | 7.8% |
| 27 | $283.83 | 1,617 | $459K | 7.3% |
| 28 | $283.83 | 1,617 | $459K | 7.3% |
| Total | $277.71 avg | 22,500 | $6.2M | 100% |
| Filing → |
| ALNY | SELL | 2023-08-04 | $2.2M | — | Filing → |
| BMY | BUY | 2020-06-09 | $5K | — | Filing → |
| SRPT | BUY | 2019-09-09 | $173K | — | Filing → |